Cancer Chemotherapy and Pharmacology

, Volume 84, Issue 1, pp 73–81 | Cite as

Pharmacokinetics and safety of lobaplatin plus etoposide in Chinese men older than 65 years with extensive-stage small cell lung cancer: a phase II clinical trial

  • Jianhua Chen
  • Bingyang Liu
  • Fang Zhang
  • Weiping Cui
  • Peng ZhangEmail author
Original Article



This phase II, multicenter, single arm clinical study was first performed to evaluate the therapeutic efficacy and safety of the regimen—a combination of lobaplatin (LBP) and etoposide (VP-16)—and investigate the pharmacokinetics of LBP in Chinese men older than 65 years with extensive-stage small cell lung cancer (SCLC).


Patients older than 65 were treated with the combination of LBP and VP-16 for 4–6 cycles through intravenous drip. The initial dose of VP-16 was 100 mg/m2/day for d1-d3 in each 21-day cycle, while LBP was administrated for d1 in each cycle based on creatinine clearance (Ccr), 20 mg/m2 for Ccr < 60 mL/min; 25 mg/m2 for 60 ≤ Ccr < 80 mL/min and 30 mg/m2 for Ccr ≥ 80 mL/min. Efficacy, safety and pharmacokinetics were evaluated to confirm the therapeutic effect.


Thirteen elderly patients were enrolled and three patients were discontinued. The median progress-free survival was 129 days and the median overall survival was 238 days, which caused a significantly prolonged survival rate of 38.5% and a higher disease control rate of 80%. Most frequent adverse events were mild to moderate containing leukopenia, neutropenia, anemia, nausea and anorexia. Pharmacokinetic analysis revealed that there is no significant difference between LP-D1 and LP-D2 at the same dosage level. With the dosage increasing, the elimination clearance showed a slowing tendency, especially for 30 mg/m2 group.


LBP (20, 25, 30 mg/m2) in combination with VP-16 (100 mg/m2) could inhibit the elderly SCLC disease process, prolong their survival time and reduce adverse reactions via preliminary assessment and provide guidance for further investigation.


Lobaplatin Small cell lung cancer Pharmacokinetic Elderly Phase II trial 



Authors want to thank Ph.D Zhang for support and access to biological samples.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional. Informed consent was obtained from all individual participants included in the studies.


  1. 1.
    Taromi S et al (2017) Proteasome inhibitor bortezomib enhances the effect of standard chemotherapy in small cell lung cancer. Oncotarget 8(57):97061–97078CrossRefGoogle Scholar
  2. 2.
    Imai H et al (2016) Clinical impact of post-progression survival on overall survival in elderly patients with extensive disease small-cell lung cancer. Thorac Cancer 7(6):655–662CrossRefGoogle Scholar
  3. 3.
    Sekine I et al (2004) Treatment of small cell lung cancer in the elderly based on a critical literature review of clinical trials. Cancer Treat Rev 30(4):359–368CrossRefGoogle Scholar
  4. 4.
    Kintzler PE et al (1995) Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer Treat Rev 21(1):33–64CrossRefGoogle Scholar
  5. 5.
    Perkowska-Ptasinska A et al (2018) The current management of kidney disease in the elderly. Minerva Med 109(1):41–52Google Scholar
  6. 6.
    Qingping L et al (2017) Dynamic analysis of kidney function and its correlation with nutritional indicators in a large sample of hospitalized elderly patients. Med Sci Monit 23:1956–1962CrossRefGoogle Scholar
  7. 7.
    Gazdar AF et al (2017) Small-cell lung cancer: what we know, what we need to know and the path forward. Nat Rev Cancer 17(12):765CrossRefGoogle Scholar
  8. 8.
    Igawa S et al (2018) Efficacy of platinum-based chemotherapy for relapsed small-cell lung cancer after amrubicin monotherapy in elderly patients and patients with poor performance status. Oncology 94(4):207–214CrossRefGoogle Scholar
  9. 9.
    Kalemkerian GP (2016) Combination chemotherapy for relapsed small-cell lung cancer. Lancet Oncol 17(8):1033–1035CrossRefGoogle Scholar
  10. 10.
    Peng Y et al (2015) A phase I clinical trial of dose escalation of lobaplatin in combination with fixed dose docetaxel for the treatment of human solid tumours that had progressed following chemotherapy. Oncol Lett 9(1):67–74CrossRefGoogle Scholar
  11. 11.
    Cao CL et al (2017) Acute pancreatitis induced by etoposide-lobaplatin combination chemotherapy used for the treatment of lung cancer: a case report and literature review. Medicine (Baltimore) 96(29):e7601CrossRefGoogle Scholar
  12. 12.
    Yu S et al (2018) Antitumor effects of carbon nanotube-drug complex against human breast cancer cells. Exp Ther Med 16(2):1103–1110CrossRefGoogle Scholar
  13. 13.
    Jain N et al (1996) Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin. Cancer 77(9):1797–1808CrossRefGoogle Scholar
  14. 14.
    Dilruba S et al (2016) Platinum-based drugs: past, present and future. Cancer Chemother Pharmacol 77(6):1103–1124CrossRefGoogle Scholar
  15. 15.
    Yang JS et al (2015) Comparison of efficacy and toxicity profiles between paclitaxel/lobapoatin-and cisplatin/5-fluorouracil-based concurrent chemoradiotherapy of advanced inoperable oesophageal cancer. Intern Med J 45(7):757–761CrossRefGoogle Scholar
  16. 16.
    Chen MQ et al (2015) The efficacy and toxicities of combined lobaplatin with paclitaxel as a first-line chemotherapy for advanced esophageal squamous cell carcinoma. J Thorac Dis 7(10):1749–1755Google Scholar
  17. 17.
    Gietema JA et al (1995) Phase II and pharmacokinetic study of lobaplatin in patients with relapsed ovarian cancer. Br J Cancer 71(6):1302–1307CrossRefGoogle Scholar
  18. 18.
    Hamilton G et al (2018) Pharmacogenetics of platinum-based chemotherapy in non-small cell lung cancer: predictive validity of polymorphisms of ERCC1. Expert Opin Drug Metab Toxicol 14(1):17–24CrossRefGoogle Scholar
  19. 19.
    Zang H et al (2017) Roles of microRNAs in the resistance to platinum based chemotherapy in the non-small cell lung cancer. J Cancer 8(18):3856–3861CrossRefGoogle Scholar
  20. 20.
    Ott PA et al (2017) Pembrolizumab in patients with extensive-stage small-cell lung cancer: results from the phase Ib KEYNOTE-028 study. J Clin Oncol 35(34):3823–3829CrossRefGoogle Scholar
  21. 21.
    Sun X et al (2014) Preclinical activity of lobaplatin as a single agent and in combination with taxanes for ovarian carcinoma cells. Asian Pac J Cancer Prev 15(22):9939–9943CrossRefGoogle Scholar
  22. 22.
    Du L et al (2017) Antitumor activity of Lobaplatin against esophageal squamous cell carcinoma through caspase-dependent apoptosis and increasing the Bax/Bcl-2 ratio. Biomed Pharmacother 95:447–452CrossRefGoogle Scholar
  23. 23.
    Zhang S et al (2016) An open-label, single-arm phase II clinical study of docetaxel plus lobaplatin for Chinese patients with pulmonary and hepatic metastasis of nasopharyngeal carcinoma. Anticancer Drugs 27(7):685–688CrossRefGoogle Scholar
  24. 24.
    Welink J et al (1996) Determination of the two diastereoisomers of lobaplatin (D-19466) in plasma ultrafiltrate of cancer patients with a normal or an impaired kidney or liver function by high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Appl 675(1):107–111CrossRefGoogle Scholar
  25. 25.
    Welink J et al (1999) Pharmacokinetics and pharmacodynamics of lobaplatin (D-19466) in patients with advanced solid tumors, including patients with impaired renal or liver function. Clin Cancer Res 5(9):2349–2358Google Scholar
  26. 26.
    Sone H et al (2018) Amrubicin monotherapy for elderly patients with relapsed extensive-disease small-cell lung cancer: a retrospective study. Thorac Cancer 10:1279–1284CrossRefGoogle Scholar
  27. 27.
    Zhou NN et al (2018) The efficacy and toxicity of lobaplatin-contained chemotherapy in extensive-stage small-cell lung cancer. J Cancer 9(13):2232–2236CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Pharmaceutical Analysis, School of PharmacyShenyang Pharmaceutical UniversityShenyangChina
  2. 2.Hunan Provincial Cancer HospitalChangshaChina

Personalised recommendations